Pazopanib in Primary Cardiac Angiosarcoma of the Right Atrium: A Case Report

12Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Primary heart tumors are an extremely rare oncological entity with primary cardiac sarcomas usually representing 20% of all primary cardiac tumorous lesions [Shanmugam: Eur J Cardiothorac Surg 2006;29: 925-932; Orlandi et al.: J Thorac Oncol 2010;5: 1483-1489]. Angiosarcoma is the most prevalent histology and despite a multidisciplinary approach tends to have a dismal prognosis [Shanmugam: Eur J Cardiothorac Surg 2006;29: 925-932; Fury et al.: Cancer J 2005;11: 241-247]. Based on the prevailing literature, we report a 48-year-old woman diagnosed with primary metastatic cardiac angiosarcoma who showed a severe hypersensitivity reaction to conventional chemotherapy with taxanes but an excellent response to treatment with the multitargeted receptor tyrosine kinase inhibitor pazopanib.

Cite

CITATION STYLE

APA

Schur, S., Hamacher, R., & Brodowicz, T. (2016). Pazopanib in Primary Cardiac Angiosarcoma of the Right Atrium: A Case Report. Case Reports in Oncology, 9(2), 363–367. https://doi.org/10.1159/000447088

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free